Citi Upgrades Biogen (BIIB) to Buy

February 7, 2017 6:27 AM EST Send to a Friend
Citi upgraded Biogen (NASDAQ: BIIB) from Neutral to Buy with a price target of $305.00.Analyst Dr. Robyn Karnauskas comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login